15 Hydroxyicosatetraenoic Acid - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

15 Hydroxyicosatetraenoic Acid

The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform

Ronald L. Wilson – 1st expert on this subject based on the ideXlab platform

  • A Pilot Study to Examine the Effects of an Anti-inflammatory Supplement on Eicosanoid Derivatives in Patients with Chronic Kidney Disease
    Journal of Alternative and Complementary Medicine, 2017
    Co-Authors: Brian D. Shelmadine, Rodney G. Bowden, Jennifer J. Moreillon, Matthew B. Cooke, Peiying Yang, Erika Deike, Jackson O. Griggs, Ronald L. Wilson

    Abstract:

    Abstract Background: Chronic kidney disease (CKD) is a progressive disease with an inverse relationship between kidney function and levels of inflammation and oxidative stress. Curcumin and Boswellia serrata have been reported to exert anti-inflammatory effects on the cyclooxygenase and lipoxygenase pathways. Therefore, the purpose of this study was to study the effects of a supplement containing curcumin and B. serrata on eicosanoid derivatives in early stage CKD patients who had not initiated hemodialysis. Methods: Sixteen patients with stage 2 and stage 3 CKD (56.0 ± 16.0 years, 171.4 ± 11.9 cm, 99.3 ± 20.2 kg) were randomized into a treatment group with curcumin and B. serrata or a placebo group. The dependent variables prostaglandin E2 (PGE2), 5-Hydroxyicosatetraenoic Acid, 12-Hydroxyicosatetraenoic Acid, 15Hydroxyicosatetraenoic Acid, and 13-hydroxyoctadecadienoic Acid were measured both before and after 8 weeks of supplementation. Results were analyzed by using a repeated-measures analysis of cova…

Brian D. Shelmadine – 2nd expert on this subject based on the ideXlab platform

  • A Pilot Study to Examine the Effects of an Anti-inflammatory Supplement on Eicosanoid Derivatives in Patients with Chronic Kidney Disease
    Journal of Alternative and Complementary Medicine, 2017
    Co-Authors: Brian D. Shelmadine, Rodney G. Bowden, Jennifer J. Moreillon, Matthew B. Cooke, Peiying Yang, Erika Deike, Jackson O. Griggs, Ronald L. Wilson

    Abstract:

    Abstract Background: Chronic kidney disease (CKD) is a progressive disease with an inverse relationship between kidney function and levels of inflammation and oxidative stress. Curcumin and Boswellia serrata have been reported to exert anti-inflammatory effects on the cyclooxygenase and lipoxygenase pathways. Therefore, the purpose of this study was to study the effects of a supplement containing curcumin and B. serrata on eicosanoid derivatives in early stage CKD patients who had not initiated hemodialysis. Methods: Sixteen patients with stage 2 and stage 3 CKD (56.0 ± 16.0 years, 171.4 ± 11.9 cm, 99.3 ± 20.2 kg) were randomized into a treatment group with curcumin and B. serrata or a placebo group. The dependent variables prostaglandin E2 (PGE2), 5-Hydroxyicosatetraenoic Acid, 12-Hydroxyicosatetraenoic Acid, 15Hydroxyicosatetraenoic Acid, and 13-hydroxyoctadecadienoic Acid were measured both before and after 8 weeks of supplementation. Results were analyzed by using a repeated-measures analysis of cova…

Jackson O. Griggs – 3rd expert on this subject based on the ideXlab platform

  • A Pilot Study to Examine the Effects of an Anti-inflammatory Supplement on Eicosanoid Derivatives in Patients with Chronic Kidney Disease
    Journal of Alternative and Complementary Medicine, 2017
    Co-Authors: Brian D. Shelmadine, Rodney G. Bowden, Jennifer J. Moreillon, Matthew B. Cooke, Peiying Yang, Erika Deike, Jackson O. Griggs, Ronald L. Wilson

    Abstract:

    Abstract Background: Chronic kidney disease (CKD) is a progressive disease with an inverse relationship between kidney function and levels of inflammation and oxidative stress. Curcumin and Boswellia serrata have been reported to exert anti-inflammatory effects on the cyclooxygenase and lipoxygenase pathways. Therefore, the purpose of this study was to study the effects of a supplement containing curcumin and B. serrata on eicosanoid derivatives in early stage CKD patients who had not initiated hemodialysis. Methods: Sixteen patients with stage 2 and stage 3 CKD (56.0 ± 16.0 years, 171.4 ± 11.9 cm, 99.3 ± 20.2 kg) were randomized into a treatment group with curcumin and B. serrata or a placebo group. The dependent variables prostaglandin E2 (PGE2), 5-Hydroxyicosatetraenoic Acid, 12-Hydroxyicosatetraenoic Acid, 15Hydroxyicosatetraenoic Acid, and 13-hydroxyoctadecadienoic Acid were measured both before and after 8 weeks of supplementation. Results were analyzed by using a repeated-measures analysis of cova…